Jove
Visualize
联系我们
JoVE
x logofacebook logolinkedin logoyoutube logo
关于 JoVE
概览领导团队博客JoVE 帮助中心
作者
出版流程编辑委员会范围与政策同行评审常见问题投稿
图书馆员
用户评价订阅访问资源图书馆顾问委员会常见问题
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experiments存档
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教师资源中心教师网站
使用条款与条件
隐私政策
政策

相关概念视频

Crystal Growth: Principles of Crystallization01:25

Crystal Growth: Principles of Crystallization

6.2K
Crystallization is a phase transformation process in which crystals are precipitated from a supersaturated solution or formed from other sources. During crystallization, atoms or molecules arrange themselves into a well-defined, rigid crystal lattice to minimize energy.
Initiating crystallization involves manipulating the concentration of the solute and the temperature of the solution. Since crystal growth occurs when the ratio of concentration and solubility of the solute in the solvent...
6.2K
Polymer Classification: Crystallinity01:21

Polymer Classification: Crystallinity

4.3K
Unlike ionic or small covalent molecules, polymers do not form crystalline solids due to the diffusion limitations of their long-chain structures. However, polymers contain microscopic crystalline domains separated by amorphous domains.
Crystalline domains are the regions where polymer chains are aligned in an orderly manner and held together in proximity by intermolecular forces. For example, chains in the crystalline domains of polyethylene and nylon are bound together by van der Waals...
4.3K
Recrystallization: Solid–Solution Equilibria01:10

Recrystallization: Solid–Solution Equilibria

4.8K
Recrystallization is a purification technique used to separate impurities from solid compounds. In this technique, no chemical reactions occur. Instead, it exploits physical properties only, specifically, the solubility differences between the desired compound and impurities, either at a single temperature or at different temperatures, and under other selected conditions. The solid-solution equilibrium (solubility equilibrium) of each component in the solution represents a binary phase...
4.8K
Factors Affecting Dissolution: Polymorphism, Amorphism and Pseudopolymorphism01:21

Factors Affecting Dissolution: Polymorphism, Amorphism and Pseudopolymorphism

892
Polymorphism refers to the existence of a drug substance in multiple crystalline forms, known as polymorphs. Recently, this term has been expanded to include solvates (forms containing a solvent), amorphous forms (non-crystalline forms), and desolvated solvates (forms from which the solvent has been removed).
Some polymorphic crystals possess lower aqueous solubility than their amorphous counterparts, leading to incomplete absorption. For instance, the oral suspension of Chloramphenicol, which...
892
Site-Targeted Drug Delivery Systems: Polymeric Carriers01:24

Site-Targeted Drug Delivery Systems: Polymeric Carriers

133
Polymeric carriers enhance targeted drug delivery by increasing efficacy while minimizing off-target effects. These carriers comprise a biodegradable polymeric backbone integrated with functional elements that enable targeting, improve physicochemical properties, and regulate drug release.Targeting MechanismsThe targeting ability of polymeric carriers is mediated by a homing device, which is a molecular recognition component designed to selectively bind to specific tissues or cells. Monoclonal...
133
Pharmaceutical Alternatives: Polymorphic Form-Related and Particle Size-Related Therapeutic Nonequivalence01:27

Pharmaceutical Alternatives: Polymorphic Form-Related and Particle Size-Related Therapeutic Nonequivalence

227
Changes in polymorphic forms can significantly influence the bioavailability of poorly soluble drugs. Although the FDA defines pharmaceutical equivalence based on having the same active ingredient, dosage form, and route of administration, it does not automatically disqualify products with different polymorphic forms. This means two products with different polymorphs can still be deemed pharmaceutically equivalent. However, polymorphic differences can affect properties like wettability,...
227

您也可能阅读

相关文章

通过共同作者、期刊和引用图与本文相关的文章。

排序
Same author

Porous Ni-based metal-organic frameworks reduce the oxygen evolution temperature of lithium perchlorate.

Dalton transactions (Cambridge, England : 2003)·2026
Same author

Quantum Coherence in a Perylene-Based Metal-Organic Framework for Potential Solid-State Qubits.

Journal of the American Chemical Society·2026
Same author

Reversible color switching of bright phosphorescence in purely organic materials for advanced data encryption.

Nature communications·2026
Same author

Transitioning Formamide Solvothermal Syntheses of MOFs to Less Toxic Solvents.

Chemistry (Weinheim an der Bergstrasse, Germany)·2025
Same author

Identification of cystatin C as a new marker of glomerular filtration rate, and of shrunken pore syndrome - a new kidney disorder defining selective glomerular hypofiltration syndromes - calls for expansion of the international KDIGO guidelines.

Scandinavian journal of clinical and laboratory investigation·2025
Same author

Elucidating the molecular structural origin of efficient emission across solid and solution phases of single benzene fluorophores.

Nature communications·2025

相关实验视频

Updated: Apr 19, 2026

Optimization of Crystal Growth for Neutron Macromolecular Crystallography
12:29

Optimization of Crystal Growth for Neutron Macromolecular Crystallography

Published on: March 13, 2021

6.1K

使用设计的聚合物异质核控制药物结晶.

Laura Y Pfund1, Christopher P Price, Jessica J Frick

  • 1Department of Chemistry and the Macromolecular Science and Engineering Program, The University of Michigan , 930 North University Avenue, Ann Arbor, Michigan 48109-1055, United States.

Journal of the American Chemical Society
|December 19, 2014
PubMed
概括

研究人员通过将它们纳入聚合物,将结晶抑制剂转化为促进剂. 这一创新显著加快了晶体形成,帮助抗结晶的化合物,并改善了固体形式的发现.

科学领域:

  • 材料科学 材料科学 材料科学
  • 化学工程是化学工程的重要组成部分.
  • 结晶科学 结晶科学

背景情况:

  • 结晶抑制剂可以阻碍所需的结晶形成.
  • 开发控制结晶运动的方法对于制药开发和材料科学至关重要.
  • 定制分子添加剂为操纵结晶过程提供了一个潜在的途径.

研究的目的:

  • 调查是否可以修改抑制溶液结晶的分子以促进其.
  • 为了合成新的可聚合添加剂,模仿乙氨基和美芬胺酸.
  • 探索将这些添加剂纳入聚合物对结晶诱导时间的影响.

主要方法:

  • 聚合性添加剂的合成,旨在模仿制药结构.
  • 在溶液中评估添加剂的性能,观察面选择性抑制和晶体生长.
  • 在不溶性聚合物矩阵中加入添加剂.
  • 在聚合物结合添加剂的存在下测量药品结晶诱导时间.

主要成果:

  • 合成的添加剂显示出溶液中的晶体生长的面选择性抑制,减缓了晶体的外观.
  • 将这些添加剂添加到不溶性聚合物中,大大减少了乙氨基和美芬胺酸晶体形成的诱导时间.
  • 聚合物结合的添加剂作为结晶促进剂,对比它们的溶液行为.

更多相关视频

Growing Protein Crystals with Distinct Dimensions Using Automated Crystallization Coupled with In Situ Dynamic Light Scattering
09:15

Growing Protein Crystals with Distinct Dimensions Using Automated Crystallization Coupled with In Situ Dynamic Light Scattering

Published on: August 14, 2018

11.1K
Synthesis of Monodisperse Cylindrical Nanoparticles via Crystallization-driven Self-assembly of Biodegradable Block Copolymers
11:42

Synthesis of Monodisperse Cylindrical Nanoparticles via Crystallization-driven Self-assembly of Biodegradable Block Copolymers

Published on: June 20, 2019

8.4K

相关实验视频

Last Updated: Apr 19, 2026

Optimization of Crystal Growth for Neutron Macromolecular Crystallography
12:29

Optimization of Crystal Growth for Neutron Macromolecular Crystallography

Published on: March 13, 2021

6.1K
Growing Protein Crystals with Distinct Dimensions Using Automated Crystallization Coupled with In Situ Dynamic Light Scattering
09:15

Growing Protein Crystals with Distinct Dimensions Using Automated Crystallization Coupled with In Situ Dynamic Light Scattering

Published on: August 14, 2018

11.1K
Synthesis of Monodisperse Cylindrical Nanoparticles via Crystallization-driven Self-assembly of Biodegradable Block Copolymers
11:42

Synthesis of Monodisperse Cylindrical Nanoparticles via Crystallization-driven Self-assembly of Biodegradable Block Copolymers

Published on: June 20, 2019

8.4K

结论:

  • 可以合成定制的聚合物,将结晶抑制剂转化为促进剂.
  • 这种方法有效地减少了晶体出现的诱导时间.
  • 该方法对抗结晶的化合物和增强固体形式中异质核的发现具有潜力.